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CD27, a member of the tumor necrosis factor receptor
superfamily, is constitutively expressed on the majority of
mature T cells, memory B cells, and a subset of NK cells.
We previously demonstrated anti-tumor and immunologi-
cal properties of the fully human anti-CD27 mAb 1F5
(CDX-1127) in murine tumor models of hematologic and
solid tumors. A Phase I dose escalation study of CDX-1127
in patients (pts) with recurrent or treatment-refractory
B-cell malignancies and select solid tumors is ongoing.
CDX-1127 (0.1 to 10 mg/kg IV) is administered as a sin-
gle-dose with 28-day observation, followed by 4 weekly
doses before restaging at Day 85. Up to 4 additional
re-treatment cycles (consisting of 4 weekly doses) are
permitted in pts with stable disease or tumor response.
Dose-escalation in pts with solid tumors has been com-
pleted with preliminary results presented in a separate
abstract. Flow cytometry and functional immune analysis
of peripheral blood lymphocytes from these solid tumor
pts showed an increase in expression of activation markers
on T cells (HLA-DR), increases in NK cells, decrease in
Tregs, and enhanced T cell response to various stimuli
in in vitro assays. Tumor shrinkage was also seen. Dose-
escalation in pts with hematologic malignancies is ongoing.
To date, 13 B-cell lymphoma pts (3 Hodgkin, 3 follicular,
3 marginal zone, 4 diffuse large B-cell) have received 0.1,
0.3, or 1 mg/kg CDX-1127, with no DLT. Treatment-
related toxicity, generally Grade 1-2, included fatigue, nau-
sea, decreased appetite and anemia. One pt with Hodgkin
lymphoma who had previously progressed following treat-
ment with chemotherapy, autologous stem cell transplant,
and brentuximab vedotin had a partial response (PR) with
77% shrinkage in measurable disease; treatment is ongoing.
Three additional pts had stable disease (range: 4.5 to 11+
months), including a pt with follicular lymphoma who has
completed 3 cycles of therapy and a pt with marginal zone
lymphoma with -36% shrinkage in measurable disease.
Flow cytometry and functional immune analysis of periph-
eral blood lymphocytes are being performed to assess the
immunomodulatory activity of CDX-1127 in patients with
hematological malignancies. Emerging results suggest that
weekly dosing of CDX-1127 is well tolerated with promis-
ing biological and early clinical activity. In addition, these
data position CDX-1127 well for combination therapy with
conventional and immunotherapy approaches as demon-
strated in preclinical models.
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